1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Aquilo Capital Management, LLC Buys AnaptysBio Inc, NGM Biopharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Sells Galapagos NV, Merus NV, Fate Therapeutics Inc

Investment company Aquilo Capital Management, LLC (Current Portfolio) buys AnaptysBio Inc, NGM Biopharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Spero Therapeutics Inc, sells Galapagos NV, Merus NV, Fate Therapeutics Inc during the 3-months ended 2020Q1, according to the most recent filings of the investment company, Aquilo Capital Management, LLC. As of 2020Q1, Aquilo Capital Management, LLC owns 14 stocks with a total value of $257 million. These are the details of the buys and sells.

For the details of Aquilo Capital Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/aquilo+capital+management%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Aquilo Capital Management, LLC
  1. SPDR Series Trust S&P Biotech (XBI) - 1,000,000 shares, 30.18% of the total portfolio.
  2. uniQure NV (QURE) - 501,975 shares, 9.28% of the total portfolio. Shares added by 26.47%
  3. Dicerna Pharmaceuticals Inc (DRNA) - 1,237,379 shares, 8.86% of the total portfolio. Shares added by 101.38%
  4. AnaptysBio Inc (ANAB) - 1,439,079 shares, 7.92% of the total portfolio. New Position
  5. Xenon Pharmaceuticals Inc (XENE) - 1,499,970 shares, 6.63% of the total portfolio. Shares added by 28.56%
New Purchase: AnaptysBio Inc (ANAB)

Aquilo Capital Management, LLC initiated holding in AnaptysBio Inc. The purchase prices were between $12.82 and $18.69, with an estimated average price of $15.2. The stock is now traded at around $18.82. The impact to a portfolio due to this purchase was 7.92%. The holding were 1,439,079 shares as of .

New Purchase: NGM Biopharmaceuticals Inc (NGM)

Aquilo Capital Management, LLC initiated holding in NGM Biopharmaceuticals Inc. The purchase prices were between $10 and $19.51, with an estimated average price of $16.41. The stock is now traded at around $22.08. The impact to a portfolio due to this purchase was 5.03%. The holding were 1,047,184 shares as of .

New Purchase: Arrowhead Pharmaceuticals Inc (ARWR)

Aquilo Capital Management, LLC initiated holding in Arrowhead Pharmaceuticals Inc. The purchase prices were between $20.56 and $63.43, with an estimated average price of $40.95. The stock is now traded at around $35.85. The impact to a portfolio due to this purchase was 4.89%. The holding were 436,514 shares as of .

Added: Dicerna Pharmaceuticals Inc (DRNA)

Aquilo Capital Management, LLC added to a holding in Dicerna Pharmaceuticals Inc by 101.38%. The purchase prices were between $13.37 and $22.58, with an estimated average price of $19.53. The stock is now traded at around $21.67. The impact to a portfolio due to this purchase was 4.46%. The holding were 1,237,379 shares as of .

Added: Spero Therapeutics Inc (SPRO)

Aquilo Capital Management, LLC added to a holding in Spero Therapeutics Inc by 57.50%. The purchase prices were between $5.27 and $10.41, with an estimated average price of $8.83. The stock is now traded at around $11.93. The impact to a portfolio due to this purchase was 2.09%. The holding were 1,818,140 shares as of .

Added: uniQure NV (QURE)

Aquilo Capital Management, LLC added to a holding in uniQure NV by 26.47%. The purchase prices were between $40.01 and $73.97, with an estimated average price of $57.92. The stock is now traded at around $58.33. The impact to a portfolio due to this purchase was 1.94%. The holding were 501,975 shares as of .

Added: Xenon Pharmaceuticals Inc (XENE)

Aquilo Capital Management, LLC added to a holding in Xenon Pharmaceuticals Inc by 28.56%. The purchase prices were between $8.08 and $17.57, with an estimated average price of $14.31. The stock is now traded at around $13.00. The impact to a portfolio due to this purchase was 1.47%. The holding were 1,499,970 shares as of .

Added: ProQR Therapeutics NV (PRQR)

Aquilo Capital Management, LLC added to a holding in ProQR Therapeutics NV by 24.91%. The purchase prices were between $5.25 and $9.91, with an estimated average price of $7.73. The stock is now traded at around $5.56. The impact to a portfolio due to this purchase was 1.03%. The holding were 2,401,570 shares as of .

Added: MorphoSys AG (MOR)

Aquilo Capital Management, LLC added to a holding in MorphoSys AG by 1477.27%. The purchase prices were between $18.86 and $37.36, with an estimated average price of $29.61. The stock is now traded at around $32.46. The impact to a portfolio due to this purchase was 0.86%. The holding were 95,898 shares as of .

Sold Out: Fate Therapeutics Inc (FATE)

Aquilo Capital Management, LLC sold out a holding in Fate Therapeutics Inc. The sale prices were between $17.28 and $31.88, with an estimated average price of $25.26.



Here is the complete portfolio of Aquilo Capital Management, LLC. Also check out:

1. Aquilo Capital Management, LLC's Undervalued Stocks
2. Aquilo Capital Management, LLC's Top Growth Companies, and
3. Aquilo Capital Management, LLC's High Yield stocks
4. Stocks that Aquilo Capital Management, LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)